يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Yee, Andrew J."', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study.

    المؤلفون: Raje, Noopur1, Yee, Andrew J.1, Puzanov, Igor2, Chau, Ian3, Kaiser, Martin3, Hyman, David M.3, Landau, Heather3, Baselga, Jose3, Ribrag, Vincent3, Michot, Jean-Marie3, Hollebecque, Antoine3, Blay, Jean-Yves3, Tabernero, Josep3, Elez, Elena3, Wolf, Jürgen3, Veronese, Luisa3, Makrutzki, Martina3, Pitcher, Bethany3

    المصدر: JCO Precision Oncology. 2018, Vol. 2, p1-9. 9p.

    مصطلحات موضوعية: *MULTIPLE myeloma treatment, *CANCER relapse, *BRAF genes, *DISEASE progression, *GENETIC mutation, *MULTIPLE myeloma, *COHORT analysis, *PROGNOSIS


    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.

    المؤلفون: Yee, Andrew J1, Bensinger, William I2, Supko, Jeffrey G1, Voorhees, Peter M3, Berdeja, Jesus G4, Richardson, Paul G5, Libby, Edward N2, Wallace, Ellen E1, Birrer, Nicole E1, Burke, Jill N1, Tamang, David L6, Yang, Min6, Jones, Simon S6, Wheeler, Catherine A6, Markelewicz, Robert J6, Raje, Noopur S1 nraje@mgh.harvard.edu

    المصدر: Lancet Oncology. Nov2016, Vol. 17 Issue 11, p1569-1578. 10p.

    مصطلحات موضوعية: *MULTIPLE myeloma treatment, *CANCER relapse, *DEXAMETHASONE, *HISTONE deacetylase inhibitors, *DRUG dosage, *DRUG efficacy, *CANCER, *ANTINEOPLASTIC agents, *CLINICAL trials, *COMPARATIVE studies, *ENZYME inhibitors, *HETEROCYCLIC compounds, *RESEARCH methodology, *MEDICAL cooperation, *MULTIPLE myeloma, *RESEARCH, *THALIDOMIDE, *HYDROXY acids, *EVALUATION research

    مصطلحات جغرافية: UNITED States


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.

    المؤلفون: Yee, Andrew J.1,2, Hari, Parameswaran3, Marcheselli, Raffaella2,4, Mahindra, Anuj K.1,2, Cirstea, Diana D.1,2,5, Scullen, Tyler A.1, Burke, Jill N.1, Rodig, Scott J.2,6, Hideshima, Teru2,5, Laubach, Jacob P.2,5, Ghobrial, Irene M.2,5, Schlossman, Robert L.2,5, Munshi, Nikhil C.2,5, Anderson, Kenneth C.2,5, Weller, Edie A.2,4, Richardson, Paul G.2,5, Raje, Noopur S.1,2

    المصدر: British Journal of Haematology. Aug2014, Vol. 166 Issue 3, p401-409. 9p.

    مصطلحات موضوعية: *HEALTH outcome assessment, *MULTIPLE myeloma treatment, *EVEROLIMUS, *THALIDOMIDE, *TOR proteins, *DOSE-response relationship in poisons, *THERAPEUTICS


    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?

    المؤلفون: Kim, E. Bridget1 (AUTHOR) ebkim@partners.org, Yee, Andrew J.2,3 (AUTHOR) ayee1@mgh.harvard.edu, Raje, Noopur2,3 (AUTHOR) nraje@mgh.harvard.edu

    المصدر: Cancers. May2020, Vol. 12 Issue 5, p1223. 1p.

    مصطلحات موضوعية: *MULTIPLE myeloma treatment, *MULTIPLE myeloma, *RISK assessment, *SURVIVAL, *DISEASE progression, *EARLY medical intervention, *DISEASE risk factors

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث